推荐产品
等级
pharmaceutical primary standard
API类
budesonide
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO
InChI
1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
InChI key
VOVIALXJUBGFJZ-KWVAZRHASA-N
基因信息
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Budesonide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.
Second generation glucocorticoid with low systemic absorption; anti-inflammatory agent; inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - Skin Sens. 1 - STOT RE 1 Inhalation
靶器官
Adrenal gland
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Maciej Kupczyk et al.
Thorax, 68(7), 611-618 (2013-04-09)
Objective measures are required that may be used as a proxy for exacerbations in asthma. The aim was to determine the sensitivity and specificity of electronic diary data to detect severe exacerbations (SEs) of asthma. A secondary aim was to
Nicole M Gentile et al.
The American journal of gastroenterology, 108(2), 256-259 (2013-01-09)
To evaluate the outcomes of corticosteroid-treated microscopic colitis (MC) in a population-based cohort, and to compare these outcomes in patients treated with prednisone or budesonide. A historical cohort study of Olmsted County, Minnesota residents diagnosed with collagenous or lymphocytic colitis
Cumali Efe et al.
Autoimmunity reviews, 11(5), 330-334 (2011-10-18)
The aim of the present study was to assess the efficacy and tolerability of budesonide as an alternative first line treatment option for autoimmune hepatitis (AIH) and the overlap syndrome. A total of 18 AIH or overlap syndrome patients were
Marek Woynarowski et al.
The Journal of pediatrics, 163(5), 1347-1353 (2013-07-03)
To compare the effect of budesonide vs prednisone therapy both in combination with azathioprine in pediatric patients with autoimmune hepatitis (AIH). Forty-six patients with AIH (11 males and 35 females) aged 9-17 years were enrolled in a 6-month, prospective, double-blind
Ana Beloqui et al.
International journal of pharmaceutics, 454(2), 775-783 (2013-05-23)
The challenge for the treatment of inflammatory bowel disease (IBD) is the delivery of the drug to the site of inflammation. Because nanoparticles have the ability to accumulate in inflamed regions, the aim of the present study was to evaluate
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门